The FDA recently issued an alert based on early findings of two new studies suggesting that paroxetine (Paxil, GlaxoSmithKline [GSK]) increases the risk for congenital malformations, particularly those of a cardiac nature, when it is taken by women during the first trimester of pregnancy.
The FDA recently issued an alert based on early findings of two new studies suggesting that paroxetine (Paxil, GlaxoSmithKline [GSK]) increases the risk for congenital malformations, particularly those of a cardiac nature, when it is taken by women during the first trimester of pregnancy.
The as-yet-unpublished epidemiology studies indicate that women who take the drug during the first 3 months of pregnancy are one and a half to two times as likely to have a baby with a heart defect as women who take other antidepressants or none at all. Most of the defects consisted of atrial and ventricular septal defects, ranging in severity from minor to requiring surgical repair.
As a result of the studies, the FDA has asked and GSK has agreed to change the pregnancy category of paroxetine from C to D, which indicates that controlled or observational studies in pregnant women have demonstrated a risk to the fetus. The manufacturer has also added information to the Warnings section of paroxetine's labeling.
Study: Plant-based diets lower hypertensive disorders of pregnancy risk
March 28th 2024A recent study suggests that adherence to plant-based diets significantly decreases the risk of developing hypertensive disorders of pregnancy, shedding light on dietary interventions for maternal health.
Read More
How genetic variables impact oral contraceptive use and VTE risk
March 27th 2024A comprehensive study delved into the interplay of polygenic and hereditary factors in venous thromboembolism risk among oral contraceptive users, shedding light on potential genetic markers for refined risk assessment and counseling.
Read More